The real-world study of the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer in China

被引：0

作者：

Cui Jiujie ^{[1
]}

Fu Qihan ^{[2
]}

Chen Xiaobing ^{[3
]}

Wang Yanling ^{[1
]}

Li Qi ^{[4
]}

Wang Feng ^{[5
]}

Li Zhihua ^{[6
]}

Dai Guanghai ^{[7
]}

Wang Yusheng ^{[8
]}

Zhang Hongmei ^{[9
]}

Liang Houjie ^{[10
]}

Zhou Jun ^{[11
,12
]}

Yang Liu ^{[13
]}

Wang Fenghua ^{[14
]}

Zheng Leizhen ^{[15
]}

Chen Xiaofeng ^{[16
]}

Gong Ping ^{[17
]}

Liu Jiang ^{[18
]}

Yuan Ying ^{[19
]}

Wang Lin ^{[20
]}

Cheng Yuejuan ^{[21
]}

Zhang Jun ^{[22
]}

Zhou Yuhong ^{[23
]}

Guo Weijian ^{[24
]}

Zhan Xianbao ^{[25
]}

Zou Zhengyun ^{[26
]}

Li Da ^{[27
]}

Zeng Shan ^{[28
]}

Li Enxiao ^{[29
]}

Li Zhiwei ^{[30
]}

Teng Zan ^{[31
]}

Cao Dan ^{[32
]}

Kan Jie ^{[33
]}

Xiong Jianping ^{[34
]}

Quan Ming ^{[35
]}

Yao Jiayu ^{[1
]}

Yang Haiyan ^{[1
]}

Wang Liwei ^{[1
]}

机构：

[1] Department of Medical Oncology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

[2] Department of Medical Oncology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

[3] Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China

[4] Department of Medical Oncology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China

[5] Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China

[6] Department of Medical Oncology, Sun Yat-sen Medical Hospital Sun Yat-sen University, Guangzhou, China

[7] Medical Oncology, Chinese PLA General Hospital, Beijing, China

[8] Department of Gastrointestinal Oncology, Shanxi Provincial Cancer Hospital, Affiliated to Shanxi Medical University, Taiyuan, China

[9] Department of Clinical Oncology, Xijing Hospital, Air Force Medical University, Xi’an, China

[10] Department of Oncology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University (Army Military Medical University), Chongqing, China

[11] Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/ Beijing), Peking University Cancer Hospital &amp

[12] Institute, Beijing, China

[13] Cancer Center, Department of Medical Oncology, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou, China

[14] Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, China

[15] Oncology Department, Xin Hua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Shanghai, China

[16] Department of Oncology, the First Affiliated Hospital with Nanjing Medical University, Nanjing, China

[17] Department of Oncology, The First Affiliated Hospital, School of Medicine, Shihezi University, Shihezi, China

[18] Department of Oncology, People’s Hospital of Xinjiang Uygur Autonomous Region, Xinjiang, China

[19] Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China

[20] Department of Medical Oncology, Hainan Genderal Hospital, Haikou, China

[21] Division of Medical Oncology, Peking Union Medical College Hospital, Beijing, China

[22] Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

[23] Department of Medical Oncology, Shanghai Zhongshan Hospital, Fudan University, Shanghai, China

[24] Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

[25] Department of Medical Oncology, Changhai Hospital of Shanghai, Navy Medical University, Shanghai, China

[26] Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, China

[27] Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, China

[28] Department of Medical Oncology, Xiangya Hospital Central South University, Changsha, China

[29] Department of Medical Oncology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China

[30] Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China

[31] Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China

[32] Department of Medical Oncology, West China Hospital, Sichuan University, Chengdu, China

[33] Department of Medical Oncology, Qinghai Provincial People’s Hospital, Xi’ning, China

[34] Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, China

[35] Department of Oncology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai,

来源：

胰腺病学杂志（英文） | 2024年 / 07卷 / 01期

关键词：

Advanced pancreatic cancer; China Pancreas Data Center; Chinese; First-line regimens; Real-world study;

D O I：

暂无

中图分类号：

R735.9 [胰腺肿瘤];

学科分类号：

摘要：

Objective: Real-world diagnostic and treatment data for pancreatic cancer in China are lacking. As such, the present study investigated the clinical characteristics, diagnosis, and treatment of advanced pancreatic cancer (including locally advanced and metastatic disease) in the Hospital-based Advanced Pancreatic Cancer Cohort in China of the China Pancreas Data Center database.Methods: A total of 5349 Chinese patients with advanced pancreatic cancer were identified from a database. The entire course of real-world pancreatic cancer management was analyzed.Results: The proportion of patients with advanced pancreatic cancer was higher among males than females (62.4% vs 37.6%, respectively). Patients typically had a history of hypertension (30.8%), diabetes (21.6%), and cholangitis (20.2%). Abdominal pain (51.6%), abdominal distension (27.1%), jaundice (20.1%), and weight loss (16.3%) were the main symptoms observed in patients with advanced pancreatic cancer in this cohort. Serum carbohydrate antigen (CA)19-9 is one of the most common tumor markers. In the present study, 2562 patients underwent first-line therapy. The median progression-free survival (PFS) for patients undergoing first-line therapy was 4.1 months. The major options for first-line therapy included gemcitabine (GEM) plus S-1 (GS/X) (23.4%), nab-paclitaxel plus GEM (AG) (18.1%), oxaliplatin, irinotecan, and leucovorin-modulated fluorouracil (FOLFIRINOX; 11.9%), nab-paclitaxel plus S-1 (AS) (8.9%), and GEM combined with oxaliplatin/cisplatin (GEMOX/GP) (7.6%). The AS and GS/X regimens were associated with the highest PFS rates.Conclusion: This is the first study to report multicenter, real-world data regarding advanced pancreatic cancer in China. Results revealed that real-world treatment options differed from guideline recommendations, and PFS was shorter than that in previously reported data. Improving intelligent follow-up systems and standardizing diagnosis and treatment of pancreatic cancer is recommended.

引用

共 58 条

[1] Cancer statistics, 2023
Siegel, Rebecca L.
Miller, Kimberly D.
Wagle, Nikita Sandeep
Jemal, Ahmedin
[J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2023, 73 (01) : 17 - 48
[2] Insight of pancreatic cancer: recommendations for improving its therapeutic efficacy - a narrative review.[J].Xu Zhihang;Wang Wenquan;Lou Wenhui;Liu Liang.Journal of Pancreatology.2022,
[3] GATA2-Mediated Transcriptional Activation of Notch3 Promotes Pancreatic Cancer Liver Metastasis
Lin, Heng
Hu, Peng
Zhang, Hongyu
Deng, Yong
Yang, Zhiqing
Zhang, Leida
[J]. MOLECULES AND CELLS, 2022, 45 (05) : 329 - 342
[4] Real-world study of surgical treatment of pancreatic cancer in China: Annual Report of China Pancreas Data Center (2016–2020).[J].Wu Wenming;Miao Yi;Yang Yinmo;Lou Wenhui;Zhao Yupei.Journal of Pancreatology.2022,
[5] Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer.[J].Zhang Xiaofei;Mao Tiebo;Zhang Bei;Xu Haiyan;Cui Jiujie;Jiao Feng;Chen Dongqin;Wang Yu;Hu Jiong;Xia Qing;Ge Weiyu;Li Shumin;Yue Ming;Ma Jingyu;Yao Jiayu;Wang Yongchao;Wang Yanling;Shentu Daiyuan;Zhang Xiao;Chen Shiqing;Bai Yuezong;Wang Yuexiang;Zhang Xuebin;Liu Qiang;Sun Yongwei;Fu Deliang;Liu Yingbin;Xiong Lei;Wang Liwei.eBioMedicine.2022,
[6] Outcomes of lung metastasis from pancreatic cancer: A nationwide multicenter analysis
Homma, Yuki
Endo, Itaru
Matsuyama, Ryusei
Sho, Masayuki
Mizuno, Shugo
Seyama, Yasuji
Hirano, Satoshi
Aono, Takashi
Kitami, Chie
Morita, Yoshifumi
Takeda, Yutaka
Yoshida, Kazuhiro
Tani, Masaji
Kaiho, Takashi
Yamamoto, Yuzo
Aoki, Hideki
Ogawa, Masao
Niguma, Takefumi
Mataki, Yuko
Kawasaki, Hiroshi
Baba, Hideo
Yokomizo, Hiroshi
Rikiyama, Toshiki
Yamaue, Hiroki
Yamamoto, Masakazu
[J]. JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2022, 29 (05) : 552 - 561
[7] Characterization of DNA damage response deficiency in pancreatic cancer patients from China..[J].Zhang Xiaofei;Mao Tiebo;Zhang Bei;Xu Haiyan;Cui Jiujie;Jiao Feng;Chen Dongqin;Wang Yu;Hu Jiong;Xia Qing;Li Shumin;Yue Ming;Ma Jingyu;Yao Jiayu;Wang Yongchao;Zhang Xiao;Chen Shiqing;Bai Yuezong;Wang Yuexiang;Zhang Xuebin;Liu Qiang;Sun Yongwei;Fu Deliang;Liu Yingbin;Xiong Lei;Wang Liwei.Cancer communications (London; England).2021, 1
[8] Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Sung, Hyuna
Ferlay, Jacques
Siegel, Rebecca L.
Laversanne, Mathieu
Soerjomataram, Isabelle
Jemal, Ahmedin
Bray, Freddie
[J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2021, 71 (03) : 209 - 249
[9] Cancer Statistics, 2021
Siegel, Rebecca L.
Miller, Kimberly D.
Fuchs, Hannah E.
Jemal, Ahmedin
[J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2021, 71 (01) : 7 - 33
[10] Chart review of diagnostic methods; baseline characteristics and symptoms for European patients with pancreatic cancer.[J].Carrato Alfredo;Melisi Davide;Prager Gerald;Westphalen Christoph B;Ferreras Anabel;D’Esquermes Nathalie;Taieb Julien;Mercadé Teresa M.Future Oncology.2021, 0

← 1 2 3 4 5 6 →